Clinical Trial Update: Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

View source ↗

Summary

Clinical trial update reporting safety and efficacy data for crizotinib under a regulatory post-marketing commitment plan for non-small cell lung cancer. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED | Results posted: 2019-09-13